Newsfeeds - Spark Newswire - Page 9

Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Read More

1 minute read

Syndax Pharma, Incyte Ink Licensing Pact For Graft Vs. Host Disease Candidate

By Vandana Singh

Today, 3:44 PM

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) and Incyte Corporation (NASDAQ:INCY) have entered into an exclusive worldwide collaboration and license agreement to develop and commercialize Syndax’s…

Read More

1 minute read

Analyst Ratings

Expert Ratings For Incyte

By Benzinga Insights

Today, 3:44 PM

Over the past 3 months, 5 analysts have published their opinion on Incyte (NASDAQ:INCY) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Read More

1 minute read

Incyte, Knight Therapeutics Ink Distribution Pact For Two Cancer Drugs In Latin America

By Vandana Singh

Today, 3:44 PM

Knight Therapeutics Inc has acquired exclusive rights from Incyte Corporation (NASDAQ:INCY) to distribute tafasitamab and pemigatinib (Pemazyre) in Latin America. Related: Incyte’s Pemazyre…

Read More

11 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For September 23, 2021

By Benzinga Insights

Today, 3:44 PM

Read More

1 minute read

Morgan Stanley Maintains Equal-Weight on Incyte, Lowers Price Target to $80

By vishwanath@benzinga.com

Today, 3:44 PM

Morgan Stanley analyst Vikram Purohit maintains Incyte (NASDAQ:INCY) with a Equal-Weight and lowers the price target from $85 to $80.

Read More

3 minute read

BriaCell’s Survival Story Could Mean a Better Chance of Survival for Women Suffering from Breast Cancer

Today, 3:44 PM

Photo by Artem Podrez from Pexels

Read More

4 minute read

The Daily Biotech Pulse: Restricted Authorization For Pfizer’s COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data

By Shanthi Rexaline

Today, 3:44 PM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22)

Read More

1 minute read

10 Biggest Price Target Changes For Thursday

Today, 3:44 PM

Deutsche Bank reduced the price target for FedEx Corporation (NYSE: FDX) from $375 to $280. FedEx rose 0.5% to $230.18 in pre-market trading.

Read More

1 minute read

RBC Capital Maintains Sector Perform on Incyte, Lowers Price Target to $86

By Benzinga Newsdesk

Today, 3:44 PM

RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and lowers the price target from $91 to $86.

Read More

1 minute read

SVB Leerink Upgrades Incyte to Market Perform, Lowers Price Target to $66

By Benzinga Newsdesk

Today, 3:44 PM

SVB Leerink analyst Andrew Berens upgrades Incyte (NASDAQ:INCY) from Underperform to Market Perform and lowers the price target from $67 to $66.